Literature DB >> 11479226

Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice.

D Yang1, G E Holt, M P Velders, E D Kwon, W M Kast.   

Abstract

To identify genes that are differentially up-regulated in prostate cancer of transgenic adenocarcinoma mouse prostate (TRAMP) mice, we subtracted cDNA isolated from mouse kidney and spleen from cDNA isolated from TRAMP-C1 cells, a prostate tumor cell line derived from a TRAMP mouse. Using this strategy, cDNA clones that were homologous to human six-transmembrane epithelial antigen of the prostate (STEAP) and prostate stem cell antigen (PSCA) were isolated. Mouse STEAP (mSteap) is 80% homologous to human STEAP at both the nucleotide and amino acid levels and contains six potential membrane-spanning regions similar to human STEAP. Mouse PSCA (mPsca) shares 65% homology with human PSCA at the nucleotide and amino acid levels. mRNA expression of mSteap and mPsca is largely prostate-specific and highly detected in primary prostate tumors and metastases of TRAMP mice. Both mSteap and mPsca map to chromosome 5. Another known gene coding for mouse prostate-specific membrane antigen (mPsma) is also highly expressed in both primary and metastatic lesions of TRAMP mice. These results indicate that the TRAMP mouse model can be used to effectively identify genes homologous to human prostate-specific genes, thereby allowing for the investigation of their functional roles in prostate cancer. mSteap, mPsca, and mPsma constitute new tools for preventative and/or therapeutic vaccine construction and immune monitoring in the TRAMP mouse model that may provide insights into the treatment of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479226

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.

Authors:  Andrew Gray; Maria de la Luz Garcia-Hernandez; Myrna van West; Shreya Kanodia; Bolyn Hubby; W Martin Kast
Journal:  Vaccine       Date:  2009-12-30       Impact factor: 3.641

2.  Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Authors:  David A Rodeberg; Rebecca A Nuss; Sherine F Elsawa; Esteban Celis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

3.  Knockdown of STEAP1 inhibits cell growth and induces apoptosis in LNCaP prostate cancer cells counteracting the effect of androgens.

Authors:  Inês Margarida Gomes; Sandra Moreira Rocha; Carlos Gaspar; Maria Inês Alvelos; Cecília Reis Santos; Sílvia Socorro; Cláudio Jorge Maia
Journal:  Med Oncol       Date:  2018-02-20       Impact factor: 3.064

4.  Gene expression profiling: cell cycle deregulation and aneuploidy do not cause breast cancer formation in WAP-SVT/t transgenic animals.

Authors:  Andreas Klein; Eva Guhl; Raphael Zollinger; Yin-Jeh Tzeng; Ralf Wessel; Michael Hummel; Monika Graessmann; Adolf Graessmann
Journal:  J Mol Med (Berl)       Date:  2005-01-21       Impact factor: 4.599

5.  DNA Vaccines for Prostate Cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Laura E Johnson; Brian M Olson
Journal:  Curr Cancer Ther Rev       Date:  2012-11-01

6.  Kinetics of tumor destruction by chimeric antigen receptor-modified T cells.

Authors:  Usanarat Anurathapan; Robert C Chan; Hakeem F Hindi; Roopa Mucharla; Pradip Bajgain; Brendan C Hayes; William E Fisher; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Mol Ther       Date:  2013-11-28       Impact factor: 11.454

7.  STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland.

Authors:  Cláudio J B Maia; Sílvia Socorro; Fernando Schmitt; Cecília R A Santos
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

8.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Authors:  Yi T Koh; Andrew Gray; Sean A Higgins; Bolyn Hubby; W Martin Kast
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

9.  Transforming the prostatic tumor microenvironment with oncolytic virotherapy.

Authors:  Matthew J Atherton; Kyle B Stephenson; Fanny Tzelepis; David Bakhshinyan; Jake K Nikota; Hwan Hee Son; Anna Jirovec; Charles Lefebvre; Anna Dvorkin-Gheva; Ali A Ashkar; Yonghong Wan; David F Stojdl; Eric C Belanger; Rodney H Breau; John C Bell; Fred Saad; Sheila K Singh; Jean-Simone Diallo; Brian D Lichty
Journal:  Oncoimmunology       Date:  2018-03-27       Impact factor: 8.110

10.  Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.

Authors:  Bin Liu; Fraser Conrad; Audrey Roth; Daryl C Drummond; Jeff P Simko; James D Marks
Journal:  J Mol Med (Berl)       Date:  2007-06-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.